Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumour-targeted immuno-oncology therapeutics, announced yesterday that it has named Joseph Farmer as its new Chief Operating Officer.
Farmer will lead Akrevia's business development, finance, administrative, and business operations functions. He will report to Rene Russo, PharmD, Akrevia's Chief Executive Officer.
Farmer is a biopharma executive with more than 20 years of industry experience. Prior to joining Akrevia, he most recently served as Senior Vice President, General Counsel, and Corporate Secretary at Tesaro, Inc. Prior to Tesaro, he was Chief Corporate Counsel and Assistant Secretary at Cubist Pharmaceuticals Inc.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis